Latest news - Johnson & Johnson
Sep 10, 2024 · A collection of stories that highlight the way Johnson & Johnson is making an impact in the lives of its consumers, and the latest press releases from the company.
Press Releases - Johnson & Johnson
6 days ago · Johnson & Johnson reports Q3 2024 results. • 2024 Third-Quarter reported sales growth of 5.2% to $22.5 Billion with operational growth of 6.3%* and adjusted operational growth of 5.4%* • 2024 Third-Quarter Earnings per share (EPS) of $1.11 decreasing by 34.3% due to a one-time special charge and acquired IPR&D. Adjusted EPS of $2.42 ...
Johnson & Johnson Announces Real-World Evidence and Phase 3 …
Sep 21, 2021 · 74 percent efficacy in the U.S. against severe/critical COVID-19 (CI, 39%-91%); 89 percent against hospitalization (CI, 24%-100%); 83 percent against COVID-19-related death (CI, 41%-97%). Booster shot at two months provided 94 …
Investor Relations | Johnson & Johnson
6 days ago · You should view the News section and the most recent SEC Filings in the Investor section in order to receive the most current information made available by Johnson & Johnson Services, Inc. Contact us with any questions or search this site for more information.
Johnson & Johnson: Changing health for humanity
How Johnson & Johnson is fighting counterfeit medical products Fake medication and compromised devices are part of a global market that poses a significant threat to the health of patients. Here’s how the company’s Global Brand Protection team helps keep people safe.
News | Johnson & Johnson - Investors
6 days ago · You should view the News section and the most recent SEC Filings in the Investor section in order to receive the most current information made available by Johnson & Johnson Services, Inc. Contact us with any questions or search this site for more information.
Johnson & Johnson Announces Key Drivers for Long-Term …
Dec 5, 2023 · At today’s meeting, members of Johnson & Johnson’s Executive Committee and leaders from the Innovative Medicine and MedTech businesses will highlight the Company’s key drivers for sustained competitive growth and value creation.
Media Center - Johnson & Johnson
Oct 15, 2010 · Read the latest press releases from Johnson & Johnson, find our press contacts and see our latest social media posts.
Johnson & Johnson COVID-19 Vaccine Authorized by U.S. FDA For …
Johnson & Johnson is committed to making its COVID-19 vaccine available on a not-for-profit basis for emergency pandemic use. The Company has begun shipping its COVID-19 vaccine and expects to deliver enough single-shot vaccines by the end of March to enable the full vaccination of more than 20 million people in the U.S.
News Details - Investors
Aug 20, 2024 · Johnson Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) approved RYBREVANT ® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 …